AJR Custom publishing of AJR articles and ARRS Cat. Course
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carlos, R. C.
Right arrow Articles by Fendrick, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carlos, R. C.
Right arrow Articles by Fendrick, A. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?
AJR 2003; 181:1653-1661
© American Roentgen Ray Society

Incorporating Patient-Centered Outcomes in the Analysis of Cost-Effectiveness: Imaging Strategies for Renovascular Hypertension

Ruth C. Carlos1, David A. Axelrod2, James H. Ellis1, Paul H. Abrahamse3 and A. Mark Fendrick3

1 Department of Radiology, University of Michigan, 1500 E Medical Center Dr., Ann Arbor, MI 48109-0030.
2 Department of Surgery, University of Michigan, Ann Arbor, MI 48109-0030.
3 Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-0030.

OBJECTIVE. Our aim was to assess the contribution of patient-centered short-term disutilities and quality-of-life measures in the cost-effectiveness analysis of CT angiography, MR angiography, and conventional angiography in patients with medication-resistant hypertension.

MATERIALS AND METHODS. A decision analytic model compared the life expectancy and incremental cost per life year using three initial diagnostic tests in a cohort of hypothetical individuals with medication-resistant hypertension over a range of renal artery stenosis probabilities: CT angiography (sensitivity, 96%; specificity, 96%; cost, $865); MR angiography (98%, 94%, $850); and conventional angiography (99%, 99%, $2,627). All imaging strategies were compared with a base case scenario mimicking the natural history of medication-resistant hypertension and with a scenario immediate enhanced medical therapy without prior imaging. Individuals without evidence of renal artery stenosis on initial testing underwent conventional angiography if enhanced medical therapy failed to control hypertension. Individuals diagnosed with renal artery stenosis on MR angiography required conventional angiography for definitive stent treatment ($11,1223). Blood pressure response to renal artery stenting or enhanced medical therapy varied according to blood pressure, as did the incidence of myocardial infarction and stroke resulting from hypertension. Patients who progressed to end-stage renal disease received dialysis ($60,000 per year). Quality-of-life adjustments were made for patients with hypertension, end-stage renal disease, myocardial infarction, and stroke. Short-term disutilities from undergoing an imaging test were included. The analysis accounted for direct costs derived from Medicare reimbursements and total costs derived from the literature.

RESULTS. All imaging strategies were cost-effective compared with enhanced medical therapy alone or with natural history. When only direct costs were considered, MR angiography was the preferred strategy, with conventional angiography as a cost-effective alternative to MR angiography. When total costs were considered, conventional angiography dominated all other strategies. Adjusting for quality of life decreased the incremental cost-effectiveness ratios, making an already competitive strategy a more favorable alternative to the base case. Adjusting for test-related disutility did not significantly influence the cost-effectiveness of any of the imaging tests. Despite marked variation in the key clinical and cost variables, MR angiography remained the most cost-effective strategy.

CONCLUSION. In the evaluation and treatment of medication-resistant hypertension, strategies that included preliminary imaging saved more lives than did the immediate institution of enhanced medical therapy at a lesser cost.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 RadiologyHome page
D. van Helvoort-Postulart, C. D. Dirksen, P. J. Nelemans, A. A. Kroon, A. G. H. Kessels, P. W. de Leeuw, G. B. C. Vasbinder, J. M. A. van Engelshoven, and M. G. M. Hunink
Renal Artery Stenosis: Cost-effectiveness of Diagnosis and Treatment
Radiology, August 1, 2007; 244(2): 505 - 513.
[Abstract] [Full Text] [PDF]

Home page
 PERSPECT VASC SURG ENDOVASC THERHome page
T. J. Vrtiska, J. G. Fletcher, and C. H. McCollough
State-of-the-Art Imaging With 64-Channel Multidetector CT Angiography
Perspectives in Vascular Surgery and Endovascular Therapy, March 1, 2005; 17(1): 3 - 8.
[Abstract] [PDF]

Home page
 Am. J. Roentgenol.Home page
J. P. Bolduc, V. L. Oliva, E. Therasse, M.-F. Giroux, L. Bouchard, P. Perreault, A. Cliche, and G. Soulez
Diagnosis and Treatment of Renovascular Hypertension: A Cost-Benefit Analysis
Am. J. Roentgenol., March 1, 2005; 184(3): 931 - 937.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Roentgen Ray Society.